Table 2.
Details of disease, treatment, and outcome of the 13 patients.
| Patient | Age | Diagnosis date | Receptor | Stage | Treatment line | Trastuzamab Deruxtecan (T-DXd) duration | Dose | Response | |
|---|---|---|---|---|---|---|---|---|---|
| 3+ | Patient A | 60 | 2016/04/09 | ER- PR- HER2 3+ | cT2N1M0->T2N1miM0 | neoH + P -> TH ->-> Xeloda±TDM-1->-> H-> TDM-1 > Xeloda±Tykerb-> HP + Navelbine -> TDM-1 (2021/02~2022/04) | 2022/04/27 ~ now | 200 mg (46.5 kg) 4.3 mg/kg |
Almost complete |
| 3+ | Patient B | 52 | 2017/11/01 | ER + PR- HER2 3+ | cT2N1M0->pT1cN0M0 | neoH + P-> hormone-> TPH->Navelibin + P-> P -> ENHERTU x3 -> Vinorelbine | 2022/06/22-2022/08/03 | 300 mg (59 kg) 5.1 mg/kg |
Partial |
| 3+ | Patient C | 55 | 2019/11/06 | ER- PR- HER2 3+ | cT2N1M0-> pT0NxM0 | Pharmorubicin + endoxan-> TPH-> H -> TDM-1 (2021/10) -> ENHERTU (2022/05) × 3 -> Xeloda | 2022/05/11-2022/06/22 | 291 mg (54.7 kg) 5.3 mg/kg |
Partial |
| 3+ | Patient D | 56 | 2005/05/29 | ER + PR- HER2 3+ | cT2N1M0 ->pT1bN0M0 | Taxotere + Epirubicin-> H ->TDM-1(2015/03/18) -> Lapatinib(2015/06/03)->Halaven (2015/8/03) -> xeloda + lapatinib(2016/01) -> xeloda + lapatinib + AI (2018/01) -> kadcyla (2021/04) ->Perjeta(2021/06) ->capcitabin + AI -> Vinorelbin + AI (2023/05) ->ENHERTU (2023/06) | 2023/06/21 ~ still using (one cycle) |
300 mg (65 kg) 4.61 mg/kg |
Partial |
| 3+ | Patient E | 51 | 2019/01/03 | ER + PR + HER2 3 | cT4bN3aM1-> pT3N3aM0 | Neo Kadcyla (2019/01) -> Neo H + P (2019/04) -> op(2019/09) -> TPH (2019/11) -> H (2020/05) -> HP + Navelbine (2020/07) -> H (2021/06) -> Enhertu (2023/06) | 2023/06/04 ~ still using (2 cycles) |
300 mg (63 kg) 4.7 mg/kg |
Partial |
| 2+/ FISH + | Patient F | 56 | 2017/06/05 | ER-PR- HER2 2+ | cT2N1M0->pT1cN0M0 | FAC -> TH (2017) -> H -> ENHERTU (2022/10) | 2022/10/21 ~ still using | 297 mg (55 kg) 5.4 mg/kg |
Almost complete |
| 2+/ FISH + | Patient G | 61 | 2018/10/24 | ER-PR- HER2 2+ | cT2N1M0 -> pTxN0M0 | neoHP + T-> H -> ENHERTU(2022/05–09)-> Nerlynx(2022/10 - now) | 2022/05/25-2022/09/07 | 300 mg (67 kg) 4.48 mg/kg |
Partial |
| 2+/FISH− | Patient H | 59 | 2021/09/02 | ER + PR- HER2 2+ | cT2N3M0->pT2N0M0 | neoEC + T -> Femera + RT -> Ibrance (2022/06)-> ENHERTU (2022/07) | 2022/07/20 ~ still using | 300 mg (52 kg) 5.77 mg/kg |
Almost complete |
| 2+/ FISH− | Patient I (BRCA2+) | 62 | 2012/12/04 | ER + PR + HER2 2+ | cT2N0M0 ->pT2N0M0 | TC + RT-> Hormone(T-F) ->Ibrance (2019/02) ->Halaven(2020/10) → Talazoparib(2022/02-2022/12) -> ENHERTU(2023/02)-> Talazoparib(2023/05) | 2023/02/02-2023/04/12 | 200 mg (53 kg) 3.77 mg/kg |
equivocal |
| 1+ | Patient J | 45 | 2016/09/20 | ER + PR + HER 2 1+ | cT3N1M0->pT2N1M0 | neoEC -> neoTE->Ibrance(2020/12)-> Halaven(2021/04)-> Ixempra(2021/10)->-Vinorelbine(2022/06)->ENHERTU(2022/11) | 2022/11/16~2023/01/18 | 300 mg (56 kg) 5.3 mg/kg |
No response |
| 1+ | Patient K | 69 | 2017/01/23 | ER + PR + HER2 1+ | cT3N1M0->pT1cN2M0 | neoEC + T -> RT + Nolvadex→Femara -> KISQALI + Femara (2021/09 -2023/02) -> ENHERTU(2023/02) | 2023/02/22~ still using | 286 mg (53 kg) 5.39 mg/kg |
Partial response |
| 0+ | Patient L | 53 | 2017/03/20 | ER-PR- HER2 - | cT1bN0M0->pT1bN0M0 | FAC ->IORT->RT ->TDM-1(2020/10)->H + P (2020/12)-> C + T (2021/02)-> TDM-1 (2021/09)->H + P(2022/03)-> ENHERTU (2022/05) | 2022/05/04-2022/12/23 | 300 mg (54.8 kg) 5.47 mg/kg |
Partial response |
| 0+ | Patient M | 74 | 2012/01/05 Lt BC. 2022/03 R’t BC |
ER + PR - Her 2 3+ -----------ER- PR- HER2 - |
cT2N0M0 -> pT1N0M0 -------------- pT2N3aM0 |
Cysplatin + T + kytruda + RT -> Enhertu (2023/06) | 2023/6/28~ | 300 mg (58 kg) 5.17 mg/kg |
Partial response |